Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 14/20 | 0.41 |
| ▸ | ADM2 | Q7Z4H4 | 3/20 | 0.40 |
| ▸ | RAMP1 | O60894 | 8/20 | 0.40 |
| ▸ | CALCB | P10092 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CALCA | P06881 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637925 | 1.00 | CALCRL (0.41) | CALCRLADM2RAMP1CALCBKCNH2 | |
| SCHEMBL30637931 | 1.00 | CALCRL (0.41) | CALCRLADM2RAMP1CALCBKCNH2 | |
| SCHEMBL30637900 | 1.00 | CALCRL (0.41) | CALCRLADM2RAMP1CALCBKCNH2 | |
| SCHEMBL30637904 | 1.00 | CALCRL (0.41) | CALCRLADM2RAMP1CALCBKCNH2 | |
| SCHEMBL26619165 | 1.00 | CALCRL (0.41) | CALCRLADM2RAMP1CALCBKCNH2 | |
| SCHEMBL30637938 | 0.91 | CALCRL (0.44) | CALCRLADM2RAMP1CALCBCALCA | |
| SCHEMBL26619286 | 0.91 | CALCRL (0.44) | CALCRLADM2RAMP1CALCBCALCA | |
| SCHEMBL26619455 | 0.86 | CALCRL (0.41) | CALCRLADM2RAMP1CALCBCALCA | |
| SCHEMBL30637887 | 0.86 | CALCRL (0.41) | CALCRLADM2RAMP1CALCBCALCA | |
| SCHEMBL30683665 | 0.84 | CALCRL (0.40) | CALCRLADM2RAMP1CALCBCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353860-A1 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | BRISE PHARMACEUTICALS CO., LTD. (CN) | 2025-11-20 | — | — | US | disclosed |
| EP-4516793-A1 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | Brise Pharmaceuticals Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-117003762-A | Piperidine formamide aza indane derivative, preparation method and application thereof | 熙源安健医药（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353860-A1 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | CALCR, CNR2, CALCRL | CALCRL 3/4885ADM2 133/4885RAMP1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.